On June 28, 2024, Enlonstobart for Injection (Trade Name: Enshuxin®), which was initially developed by......
2024-06-28SG301 Has Completed the First Dose for the First Patient In Phase Ⅲ Clinical Trial
2024-06-15Hangzhou, China - December 27, 2023 - Hangzhou Sumgen Biotech Co., Ltd
2023-12-27Beijing R&D Center, Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. Officially established.
Sumgen Biotech was selected in“5050 Plan” of Hangzhou High-tech Zone (Binjiang).
Sumgen completed Series A financing , Led by Shanghai CCB Equity Investment Management Co., Ltd. as exclusive investor.
SG001 obtained NMPA IND approval.
Sumgen established partnership for SG001 with CSPC；
Hangzhou CMC R&D center was officially established.
Sumgen was designated as 1 of the science and technology SMEs in Zhejiang Province.
Sumgen completed Series A+ Financing, Led by China National Biotech Group (CNBG) as strategic investor.
Hangzhou Sumgen Biotech Co., Ltd. and CNBG set up the joint venture CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. ("CNBG Sumgen") .
The construction of an antibody industrialization base was launched.
Series B Financing (RMB 220 million) was completed to accelerate product development and industrialization of innovative products.
SG301 was approved in US for clinical trial.
SG404 was approved for clinical trials in China;
Sumgen was recognized as one of the Top 50 Innovative Biomedicine Enterprises of 2020 in China;
Sumgen was selected as director unit of the Biomedical Innovation Alliance (BIA) of Hangzhou High-tech Zone (Binjiang).
Clinical trial of SG404 was initiated at Beijing Cancer Hospital.
SG404 was approved by the US FDA for clinical trial.
SG12473 obtained IND in both China and the United States;
Sumgen was named of Hangzhou Unicorn Enterprise.
First patient was enrolled in the clinical trial of innovative drug SG12473;
SG301 was approved by the CN IND for clinical trial.
Core Capabilities from Antibody Discovery to Clinical Development.
Discover MoreCopyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
